Disclosures
Introduction
Gilead believes that there is strength through partnership. Collaborations of all kinds - with partners in science, academia, business and local communities - are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.
Healthcare professionals, other relevant decision makers and healthcare organizations with whom we work provide valuable, independent and expert knowledge derived from their clinical and management experience. This expertise makes an important contribution to our efforts to improve the quality of patient care, with benefits for individuals and society at large. We believe healthcare professionals, other relevant decision makers and healthcare organizations should be fairly compensated for the legitimate expertise and services they provide.
We are fully committed to compliance with healthcare spend transparency requirements which require disclosure of payments and transfers of value made to healthcare professionals, other relevant decision makers and healthcare organizations. We believe this is the right approach for industry and enhances stakeholder trust.
In line with local Transparency Reporting requirements, Gilead is disclosing its interactions with healthcare professionals and healthcare organizations in the following reports for European countries, supported by either the Gilead EFPIA Methodological Note or by a locally adapted one.
Inquiries about any of these reports should be directed here.
Gilead Sciences 2023 EFPIA Disclosure Code - Self-Certification letter
Gilead Sciences EFPIA Disclosure Code 2022 Self-certification Scheme Letter
Gilead Sciences EFPIA Disclosure Code 2021 Self-certification Scheme Letter
Gilead Sciences EFPIA Methodological Note 2022
Austria
Cyprus
Gilead Sciences Cyprus EFPIA Report 2021 (in English)
Gilead Sciences Cyprus EFPIA Report 2021 (in Greek)
Gilead Sciences EFPIA Patient Organisation Support 2021 Cyprus
Gilead Sciences Cyprus EFPIA Report 2020 (in English)
Gilead Sciences Cyprus EFPIA Report 2020 (in Greek)
Czech Republic
As of 2020, the Czech affiliate (Gilead Sciences s.r.o.) is a member of the Czech Association of Innovative Pharmaceutical Industry (AIFP). In line with our obligations to disclose payments and transfers of value, disclosure information covering the previous calendar year is published on the AIFP Disclosure platform www.transparentnispoluprace.cz annually on or around June 30. Find disclosure information for previous years below.
Get more information about Gilead operations in the Czech Republic and Slovakia
Gilead Sciences Czech Republic Methodological Note 2021 (in English)
Gilead Sciences Czech Republic Methodological Note 2021 (in Czech)
Gilead Sciences Czech Republic Methodological Note 2020 (in English)
Gilead Sciences Czech Republic Methodological Note 2020 (in Czech)
Gilead Sciences Czech Republic EFPIA Report 2019
Gilead Sciences Czech Republic Methodological Note 2019 (in Czech)
Gilead Sciences Czech Republic Methodological Note 2019 (in English)
Finland
Gilead Sciences Finland EFPIA Report 2021 (in English)
Gilead Sciences Finland EFPIA Report 2021 (in Finnish)
Gilead Sciences Finland EFPIA Methodological Note 2021 (in English)
Gilead Sciences Finland EFPIA Methodological Note 2021 (in Finnish)
Gilead Sciences Finland EFPIA Report 2020 (in English)
Gilead Sciences Finland EFPIA Report 2020 (in Finnish)
Gilead Sciences Finland EFPIA Methodological Note 2020 (in English)
Gilead Sciences Finland EFPIA Methodological Note 2020 (in Finnish)
Gilead Sciences Finland EFPIA Report 2019 (in English)
Gilead Sciences Finland EFPIA Report 2019 (in Finnish)
Gilead Sciences Finland EFPIA Methodological Note 2019 (in English)
Gilead Sciences Finland EFPIA Methodological Note 2019 (in Finnish)
Greece
Gilead Sciences Greece EFPIA Report 2021
Gilead Sciences Greece EFPIA Methodological Note 2021 (in Greek)
Gilead Sciences Greece EFPIA Report 2020
Gilead Sciences Greece EFPIA Methodological Note 2020 (in Greek)
Gilead Sciences Greece EFPIA Report 2019
Gilead Sciences Greece EFPIA Methodological Note 2019 (in Greek)
Ireland
In line with the Irish Pharmaceutical Healthcare Association code, transfers for value made to HCPs, HCOs based in Ireland, are uploaded on https://www.transferofvalue.ie on or around 30 of June covering the previous calendar year.
Enquiries about the disclosed transfers of value should be directed here.
Luxembourg
Gilead Sciences Luxembourg EFPIA Report 2021 (in English)
Gilead Sciences Luxembourg EFPIA Report 2021 (in French)
Gilead Sciences Luxembourg EFPIA Methodological Note 2021
Gilead Sciences Luxembourg EFPIA Report 2020 (in English)
Gilead Sciences Luxembourg EFPIA Report 2020 (in French)
Gilead Sciences Luxembourg EFPIA Methodological Note 2020
Gilead Sciences Luxembourg EFPIA Report 2019 (in English)
Netherlands
In line with the Commissie Geneesmiddelen Reclame (CGR) code, transfers for value made to HCPs, HCOs and Patient Organizations based in Netherlands, are uploaded on www.transparantieregister.nl on or around 31st of May covering the previous calendar year.
R&D spend is disclosed in aggregate on the affiliate’s web page.
Enquiries about the disclosed transfers of value should be directed here.
Norway
Gilead Sciences Norway EFPIA Report 2021 (in English)
Gilead Sciences Norway EFPIA Report 2021 (in Norwegian)
Gilead Sciences Norway EFPIA Methodological Note 2021 (in English)
Gilead Sciences Norway EFPIA Methodological Note 2021 (in Norwegian)
Gilead Sciences Norway EFPIA Report 2020 (in English)
Gilead Sciences Norway EFPIA Report 2020 (in Norwegian)
Gilead Sciences Norway EFPIA Methodological Note 2020 (in English)
Gilead Sciences Norway EFPIA Methodological Note 2020 (in Norwegian)
Gilead Sciences Norway EFPIA Report 2019 (in English)
Gilead Sciences Norway EFPIA Report 2019 (in Norwegian)
Gilead Sciences Norway EFPIA Methodological Note 2019 (in English)
Gilead Sciences Norway EFPIA Methodological Note 2019 (in Norwegian)
Poland
Gilead Sciences Poland EFPIA Report 2021
Gilead Sciences Poland EFPIA Methodological Note 2021 (in English)
Gilead Sciences Poland EFPIA HCO Report 2020
Gilead Sciences Poland EFPIA HCP Report 2020
Gilead Sciences Poland EFPIA R&D Report 2020
Gilead Sciences Poland EFPIA Methodological Note 2020 (in English)
Gilead Sciences Poland EFPIA HCO Report 2019
Gilead Sciences Poland EFPIA HCP Report 2019
Gilead Sciences Poland EFPIA R&D Report 2019
Gilead Sciences Poland EFPIA Methodological Note 2019 (in English)
Portugal
In line with our obligations to disclose payments and transfers of value, disclosure information in Portugal is disclosed in the Portuguese Medicines Agency transparency platform (Plataforma de Comunicações - Transparência e Publicidade do INFARMED) within 30 days of payment or transfer of value date. Click here to access the platform. To access the disclosed information, insert “Gilead Sciences.” General enquiries about the disclosure should be directed here.
Romania
Gilead Sciences Romania ARPIM Individual Disclosure 2021 (in Romanian)
Gilead Sciences Romania ARPIM R&D Disclosure 2021 (in Romanian)
Gilead Sciences Romania ARPIM Individual Disclosure 2020 (in Romanian)
Gilead Sciences Romania ARPIM R&D Disclosure 2020 (in Romanian)
Gilead Sciences Romania ARPIM Individual Disclosure 2019 (in Romanian)
Gilead Sciences Romania ARPIM R&D Disclosure 2019 (in Romanian)
Russia
Gilead Sciences Russia EFPIA Report 2021 (in Russian)
Gilead Sciences Russia EFPIA Methodological Note 2021 (in Russian)
Gilead Sciences Russia EFPIA Methodological Note 2021 (in English)
Gilead Sciences Russia EFPIA Report 2020 (in Russian)
Gilead Sciences Russia EFPIA Report 2020 (in English)
Gilead Sciences Russia EFPIA Methodological Note 2020 (in English)
Gilead Sciences Russia EFPIA Report 2019 (in Russian)
Gilead Sciences Russia EFPIA Report 2019 (in English)
Gilead Sciences Russia EFPIA Methodological Note 2019 (in English)
Slovakia
As of 2016, in line with our legal obligations to disclose payments and transfers of value, disclosure information in Slovakia is published on the National Health Information Center platform nczisk.sk every 6 months. Click here to see reports. Enquiries about the disclosed transfers of value should be directed here.
Sweden
Get more information about Gilead operations in Sweden
Gilead Sciences Sweden EFPIA Methodological Note 2021 (in English)
Gilead Sciences Sweden EFPIA Methodological Note 2021 (in Swedish)
Gilead Sciences Sweden EFPIA Methodological Note 2020 (in English)
Gilead Sciences Sweden EFPIA Methodological Note 2020 (in Swedish)
Gilead Sciences Sweden EFPIA Report 2020 (in English)
Gilead Sciences Sweden EFPIA Report 2020 (in Swedish)
Gilead Sciences Sweden EFPIA Methodological Note 2019 (in English)
Gilead Sciences Sweden EFPIA Methodological Note 2019 (in Swedish)